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Contact Dermatitis
Two decades of occupational (meth)acrylate patch test results
and focus on isobornyl acrylate
Wietske A. Christoffers, Pieter-Jan Coenraads and Marie-Louise A. Schuttelaar
Department of Dermatology, University of Groningen, University Medical Centre Groningen, 9700 RB Groningen, The Netherlands
doi:10.1111/cod.12023
Summary Background. Acrylates constitute an important cause of occupational contact
dermatitis. Isobornyl acrylate sensitization has been reported in only 2 cases. We
encountered an industrial process operator with occupational contact dermatitis caused
by isobornyl acrylate.
Objectives. (i) To investigate whether it is relevant to add isobornyl acrylate to the
(meth)acrylate test series. (ii) To report patients with (meth)acrylate contact allergy at
an occupational dermatology clinic.
Patients/materials/methods. Our patch test database was screened for positive
reactions to (meth)acrylates between 1993 and 2012. A selected group of 14 patients
was tested with an isobornyl acrylate dilution series: 0.3%, 0.1%, 0.033%, and 0.01%.
Readings were performed on D2, D3, and D7.
Results. One hundred and fifty-one patientswere testedwith our (meth)acrylate series;
24 had positive reactions. Most positive reactions were to 2-hydroxypropyl acrylate, 2-
hydroxyethyl acrylate, 2-hydroxypropyl methacrylate, and diethyleneglycol diacrylate.
Hypothetical screening with 2-hydroxypropyl acrylate, ethyleneglycol dimethacrylate,
ethoxylated bisphenol A glycol dimethacrylate and trimethylolpropane triacrylate
identified 91.7% of the 24 patients. No positive reactions were observed in 14 acrylate-
positive patients tested with the isobornyl acrylate dilution series. The 0.3% isobornyl
acrylate concentration induced irritant reactions in 3 patients.
Conclusions. We report a rare case of allergic contact dermatitis caused by isobornyl
acrylate. However, this study provides insufficient support for isobornyl acrylate to be
added to a (meth)acrylate series.
Key words: acrylate; allergic contact dermatitis; isobornyl acrylate; occupational.
Acrylates and methacrylates are important causes
of occupational contact dermatitis. Sensitization may
be induced by adhesives, dental products, ultraviolet
(UV)-cured inks, and coatings. Nail stylists, dental
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personnel, printers and industrial assembly line workers
are particularly at risk, because of daily occupational
exposure. Today, screening for (meth)acrylate contact
allergy is a topic of interest, and different screening series
have been developed (1–3).
Isobornyl acrylate (Fig. 1; CAS 5888-33-5) is a pho-
topolymerizable monomer that is used in various indus-
trial products such as UV-cured ink and UV-cured adhe-
sives. Contact allergy to isobornyl acrylate in 2 young
womenwas reported in 1995 (4). Bothwomen developed
eczema and abscesses around the injection site of their
insulin pump. They showed allergic reactions to themed-
ical adhesives and the plastic of the infusion sets upon
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Fig. 1. Chemical structure of isobornyl acrylate.
patch testingwith components of the glues and the plastic
scrapings from their infusion set, including positive reac-
tions to phenoxypoly(ethyleneoxy)ethylacrylate 0.1%,
β-carboxyethyl acrylate 0.1%, 1-benzoylcyclohexanol
1%, and isobornyl acrylate 0.1%. The latter turned out to
be one of the culprit allergens that had been used in the
UV-cured adhesive and had diffused into the plastic of the
infusion set. To the best of our knowledge, this is the only
report of isobornyl acrylate contact allergy. Other stud-
ies failed to demonstrate isobornyl acrylate sensitization,
even after prolonged exposure at high doses (3, 5, 6).
Case Report
A 47-year-old atopic man was referred to our centre
because of therapy-resistant hand eczema. He had been
working as a process operator in a factory producing
glass fibres for over 20 years. His work involved painting
glass fibres with UV-cured paint, printing the glass fibres,
covering themwith an acrylate coating, and cleaning the
machines. His skin problems cleared during holidays, and
relapsed when he returned to work.
The patient was patch tested with the European base-
line series and 12 department-specific additions, the
cosmetic series, and our (meth)acrylate series containing
29 commercially available (meth)acrylates (Chemotech-
nique Diagnostics, Vellinge, Sweden; Table 1). The patch
tests were applied on the upper back for 48 hr under
occlusion with van der Bend® square chambers (Van
der Bend BV, Brielle, The Netherlands) and Fixomull®
Stretch (BSN Medical, Hamburg, Germany). The tests
were read on D3 and D7 according to the guidelines
of the International Contact Dermatitis Research Group
(ICDRG). Therewere no positive reactions to the extended
European baseline series and the cosmetic series. The
patient showed 1+ and 2+ positive patch test reactions to
11 different (meth)acrylates (Table 1). However, all of the
acrylates turned out to be currently clinically irrelevant,
because they were not present in the substances that the
patient worked with at that moment. Nonetheless, an
acrylate was suspected to be the causative allergen, given
the nature of his present occupation. A workplace visit
Fig. 2. Strong positive reaction to isobornyl acrylate on D3.
showed that isobornyl acrylate was a component of the
glass fibre coatings [Desolite™ (DSM Desotech, Heerlen,
The Netherlands) and Bufferlite™ DU-2002 (DSM Des-
otech)] and UV-cured ink (Herkula-Ultracoat™ OF 813;
Krefeld, Germany) with which he came into contact
during the production process. Thus, isobornyl acrylate
was suspected as a relevant allergen. A patch test with
isobornyl acrylate 0.1%pet. (SigmaAldrich, Zwijndrecht,
The Netherlands; in-house preparation) under 48 hr of
occlusion resulted in a 2+ positive reaction on D3 and D7
(Fig. 2).
This case of isobornyl acrylate contact allergy and
the concomitant various positive reactions to other
clinically irrelevant acrylates led to the investigation
into potentially missed isobornyl acrylate sensitizations
in other patients. The question is whether contact allergy
to isobornyl acrylate is rare or just underdiagnosed,
and whether isobornyl acrylate should be added to
(meth)acrylate patch test series. Therefore, we screened
our database for patients with allergic reactions to
(meth)acrylates, and patch tested a selected group with
a dilution series of isobornyl acrylate, in order to detect
anymissed sensitization and potential cross-reactivity. In
addition, the results of almost 20 years of patch testing
with the (meth)acrylate patch test series are presented.
Materials and Methods
Database study
The (meth)acrylate series with 29 different (meth)
acrylates has been used for patch testing at our
dermatology department since 1993. The patch test
database was screened for the patients tested with the
(meth)acrylate series since 1993.
Our (meth)acrylate series consists of 29 different
(meth)acrylates (Table 1) supplied by Chemotechnique
Diagnostics. The types of acrylate in the series have
not been changed over the last 19 years. However, the
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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Table 1. Patch test results between January 1993 and July 2012 according to the International Contact Dermatitis Research Group (ICDRG)
guidelines
Patient number
Acrylate 1a 2b 3a 4a 5b 6b 7b 8a 9a 10b 11b 12a 13a 14b 15c 16a 17b 18a 19a 20a 21a 22b 23a 24a Total Rank
Ethyl acrylate 0.1% − + − + ? − − − − + − − + + + − − − − + + − − ? 8/151 7
Butyl acrylate 0.1%∗ − + − − − − − − + − − + − − + + − − − + + − − − 7/151 10
2-Ethylexyl acrylate 0.1% − − − − − − − − − − − − − + − − − − − − − − − − 1/151
2-Hydroxyethyl acrylate 0.1%∗ + + − + + − − + − + − ++ + − ++ + − − − + ? − − + 12/151 1
2-Hydroxypropyl acrylate 0.1%∗ − + − + + + − − + + − ++ + ? + ++ − − − + + − − − 12/151 1
Methyl methacrylate 2% ? − + − − − − IR − + − − + − − − − − + + − − − − 5/151
Ethyl methacrylate 2% + + − − − − + IR − − − − + − − − − − + + − − − − 6/151
N-Butyl methacrylate 2% − − − − − − − − − − − − + − − − − − IR IR − − − − 1/151
2-Hydroxyethyl methacrylate 2% ++ − − + − − − + − − − − + + + − − − − + − − − + 8/151 8
2-Hydroxypropyl methacrylate 2% ++ + − + − − − + − + − ++ + + + − − − − + − − − + 11/151 4
Ethyleneglycol dimethacrylate 2% ++ − − ? − − − + − + − + + + + − − − + ++ − − − + 10/151 5
Triethylene glycol dimethacrylate 2% + − − − − − − − − + − − + − + − − + − + − − − − 6/151
1,4-Butanediol dimethacrylate 2% − − − − − − − − − + ? − + − − + − + − + + − − − 6/151
Urethane dimethacrylate 2% + − − − − − − − − − − − + − − − − − − + + − − − 4/151
Bis-EMA 1% − − − − − − − − − − − − − − − IR + − − − − + + − 3/151
Bis-MA 2% − − − − − − − − − − − − − − − − − − − + − − − − 1/151
Bis-GMA 2% − − − − − − − − − − − − − − − − − − − + − + ? − 2/151
1,4-Butanediol diacrylate 0.1% − + − − − − − − + + − ++ − − − + − + − + + − − − 8/151 8
1.6-Hexanediol diacrylate 0.1% − − − − − − − − + + − − − − + + − − − ? + − − − 5/151
Diethyleneglycol diacrylate 0.1% − + − + − ++ − − − + − ++ + − + ++ − ++ − + + − − − 11/151 3
Tripropylene glycol diacrylate 0.1% − − − − − − − − − − − − − − − − − + − − ++ − − − 2/151
Trimethylolpropane triacrylate 0.1% − − − − − − − − − − + − − − − − − + − − + − − − 3/151
Pentaerythritol triacrylate 0.1% − − − − − − − − − − + − − − − − − − − − − − − − 1/151
Oligotriacrylate 0.1% − − − − − ? − − − − − − − − − − − IR IR − + − − − 1/151
Epoxy acrylate 0.5% − − − − − − − − − − − − − − − − + − − − + + − − 3/151
Urethane diacrylate (aliphatic) 0.1% − − − − − − − − − − − − − − − − − − − − − − − − 0/151
Urehane diacrylate (aromatic) 0.05% − − − − − − − − − − + − − − − − − − − − − − − − 1/151
Triethylene glycol diacrylate 0.1% − − − + − ++ − − − + − ++ − − ++ + − ++ − + + − − − 9/151 6
N,N,-Methylene bisacrylamide 1% − − − − − − − − − − − − − − − − − ++ − − − − − − 1/151
Total number of positive reactions 7 8 1 7 2 3 1 4 4 12 3 8 13 5 11 8 2 8 3 17 13 3 1 4 148
Bis-EMA, ethoxylated bisphenol A glycol dimethacrylate; Bis-GMA, bisphenol A glycidyl methacrylate; Bis-MA, 2,2-bis[4-
(methacryloxy)phenyl]propane.
∗The concentrations of butyl acrylate, 2-hydroxyethyl acrylate and 2-hydroxypropyl acrylate were 0.5% in patients 1–3 and were reduced
to 0.1% in patients 4–24.
asubject included in the isobornyl acrylate sub-study.
bsubject not included in the isobornyl acrylate sub-study.
cindex patient with a positive patch test reaction to isobornyl acrylate.
Patch test results of the (meth)acrylate series containing 29 different acrylates in pet. are given. Tests were read on D2 and D3 for patients
1–12, and on D3 and D7 for patients 13–24. Results were scored according to the ICDRG guidelines. The strongest patch test results on either
day are listed.
concentrations of butyl acrylate, 2-hydroxyethyl acrylate
(2-HEA) and 2-hydroxypropyl acrylate (2-HPA) were
reduced from0.5% to 0.1% in 2001. The patch tests were
read on D2 and D3, according to the guidelines of the
ICDRG, between January 1993 and October 2008. They
were also read on D3 and D7 between November 2008
and July 2012, in order to register late reactions.
Besides the patch test results and concomitant
reactions, patient characteristics were registered accord-
ing to the MOAHLFA index (7).
The clinical relevance and the possible exposure
to acrylates were assessed by means of a detailed
history, including occupational history and potential
exposure to acrylates. When contact with an acrylate-
containing product was suspected, Material Safety Data
Sheets (MSDSs) were studied to confirm a causative
relationship. In some cases, a workplace visit was also
undertaken.
The clinical relevance was labelled as ‘certain’ when
the patient developed an itching dermatitis after exposure
to at least one product containing acrylates (according
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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to the product label or MSDS). The clinical relevance
was labelled as ‘probable’ when a patient had developed
an itching dermatitis after exposure to one or more
products probably containing acrylates, but a specific
product had not been identified as the cause of the clinical
reaction. The clinical relevance was labelled as ‘possible’
when a patient developed an itching dermatitis after the
use of various products with or without acrylates, and
materials other than acrylates may have been the cause
of dermatitis in the patient. Finally, the clinical relevance
was labelled as ‘unlikely’ when a patient had no contact
at all with products containing acrylates as far as was
established (8, 9).
Isobornyl acrylate sub-study
Patients with a previously demonstrated acrylate sensi-
tization were selected from our patch test database and
approached by letter. The inclusion criterion was: at
least one positive reaction to a (meth)acrylate diagnosed
between January 2000 and July 2012. Patients using
oral prednisone and pregnant women were excluded.
The included subjects were patch tested with an
isobornyl acrylate dilution series of 0.3%, 0.1%, 0.033%
and 0.01% pet. The patch test consisted of van der
Bend® square chambers (Van der Bend BV, Brielle, The
Netherlands) filled with 20 mg of isobornyl acrylate (CAS
no. 5888-33-5; purity 91.8%) in pet., and fixed with
Fixomull® Stretch (BSN Medical, Hamburg, Germany).
The isobornyl acrylate was supplied by Sigma Aldrich
(Amsterdam, The Netherlands), and dilutions were
prepared in-house by our pharmacy. The patch test
syringes were stored in a refrigerator (7◦C) and freshly
prepared every 4 weeks. The patch tests were prepared
immediately prior to application, andapplied on theupper
back for 48 hr under occlusion. The results were read on
D2, D3 and D7 according to the ICDRG guidelines.
The study was approved by the Medical Ethics
Committee of the University Medical Centre Groningen.
Results
Database results
Atotal of151patientswere testedwith the (meth)acrylate
series at the dermatology department between January
1993 and July 2012. Twenty-four (15.9%) of these
151 patients had a positive reaction to at least one
acrylate (Table 1). Most of the positive reactions were
caused by 2-HPA 0.1% pet. (12/148), 2-HEA 0.1% pet.
(12/148), 2-hydroxypropyl methacrylate (2-HPMA) 2%
pet. (11/148), and diethyleneglycol diacrylate (DEGDA)
0.1% pet. (11/148), whereas no positive reactions
to urethane diacrylate (aliphatic) 0.1% pet. were
encountered. We noted 7 irritant reactions to various
acrylates, and only 10 doubtful reactionswere registered.
A minority (n = 8, 33.3%) of the patients were
males, and half of them (n = 13, 54.2%) were older
than 40 years, with a mean age of 42.7 years (range
25–65 years). Only 4 (16.7%) patients suffered from
atopic dermatitis. The MOAHLFA index was M33.3,
O87.5, A54.2, H87.5, L0.0, F12.5, A16.7. The duration
of their dermatitis ranged from 1month to 2.5 years
(mean 6 months). The duration of exposure to acrylates
varied from 2 days to 20 years, but was unknown in
several cases. The final diagnosis was ‘allergic contact
dermatitis’ in almost all of the patients (95.8%); in 1
patient, the diagnosis was hyperkeratotic hand eczema,
possibly occupationally related.
Twenty-one (87.5%) of the 24 sensitized patients had
a risk of occupational exposure, and 14 cases (66.7%)
were labelled as certainly occupation-related. Of the
remaining occupational cases, 6 cases (28.6%) were
labelledasprobablyoccupation-related,and1case (4.8%)
was labelled as possibly occupation-related. Among the
occupationally exposed patients were nail stylists (n = 8),
assembly lineworkers (n = 4), printers (n = 3), laboratory
technicians (n = 2), dental technicians (n = 2), a painter
(n = 1), and a dairy farmer (n = 1) who used a two-
component hoof glue. All of the occupational cases
presentedwithfingertipdermatitisorhandeczema,except
for 1 patient who developed facial eczema in addition to
the existing atopic dermatitis after starting training as a
nail stylist. In 2 cases, there was secondary spread, and 1
patient suffered from angioedema.
Three (12.5%) of our 24 patients with (meth)acrylate
contact allergywere considered to have been sensitized in
anon-occupationalmanner. In1case, thepatient suffered
from stomatitis caused by new dentures (relevance:
labelled as ‘certain’), whereas another case might have
been caused by the use of artificial nails (relevance:
labelled as ‘possible’). The third case developed erythema
and oedemaonher face after using an acrylate coating for
her boat (relevance: labelled as ‘certain’). The symptoms
resolved in all 3 cases after avoidance of the acrylate-
containing products.
Isobornyl acrylate sub-study
Fourteen of the 24 potential subjects were included in the
isobornyl acrylate sub-study (Fig. 3). There were various
reasons for non-inclusion: 3 subjects were excluded
because they used immunosuppressive drugs, 2 subjects
declined because they had previously developed intense
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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(meth)acrylate patch test at the UMCG
Dermatology department between
01-01-2000 and 01-07-2012  n =151
Positive reaction (at least +) for at
least one (meth) acrylate
n = 24
Included and patch tested with
isobornyl acrylate
n = 14
Excluded because of prednisone n = 3
Unwilling to participate n = 2
Untraceable n = 5
Fig. 3. Flow chart of subjects included in the isobornyl acrylate
sub-study; UMCG, University Medical Centre Groningen.
itching after patch testing, and 5 subjects either did not
respond or were untraceable.
The MOAHLFA index of the 14 included subjects
was M: 28.6, O: 85.7, A: 50.0, H: 85.7, L: 0, F: 14.3,
A: 14.2. The majority of the included subjects (n = 12,
85.7%) had a known occupational risk. Among the
occupationally exposed subjects were nail stylists (n = 6),
printers (n = 2), assembly lineworkers (n = 1), laboratory
technicians (n = 1), dental technicians (n = 1), and a
dairy farmer (n = 1) who used a two-component hoof
glue. Two (14.3%) of the 14 cases were sensitized in a
non-occupational manner.
The 14 included subjects were patch tested with the
dilution series of isobornyl acrylate: 0.3%, 0.1%, 0.033%
and 0.01% (Table 2). None of them developed a positive
patch test reaction to the isobornyl acrylate. However,
isobornyl acrylate 0.3% provoked an irritant reaction in
Table 2. Patch test results of isobornyl acrylate according to the
International Contact Dermatitis Research Group guidelines
Subject number
1 2 3 4–14
D2 D3 D7 D2 D3 D7 D2 D3 D7 D2 D3 D7
IBA 0.3% IR IR − − IR − IR IR IR − − −
IBA 0.1% − − − − − − − − − − − −
IBA 0.033% − − − − − − − − − − − −
IBA 0.01% − − − − − − − − − − − −
−, negative reaction; IBA, isobornyl acrylate (% dilution in pet.); IR,
irritant reaction.
Three subjects developed an irritant reaction to isobornyl acrylate
0.3%; none developed a positive reaction.
3 (21.4%) of the subjects. Five healthy controls were also
patch tested with the isobornyl acrylate dilution series.




Acrylates are considered to constitute an uncommon,
although important, cause of contact allergy in general
dermatology practices. The prevalence, based on screen-
ing series added to the baseline, varies between 1.0%
and 1.6% (10, 11). In our study, 24 of the 151 (15.9%)
patients patch tested with the (meth)acrylate series in
the last 19 years reacted positively to at least one acry-
late. This difference may be explained by the selected
population. At our department, (meth)acrylates are not
routinely tested, but are only tested if the physician
has a strong suspicion of acrylate contact allergy (12).
Moreover, a substantial amount of data was derived
from our Expert Centre for Eczematous and Occupational
Dermatoses, whereby most of the patients were occupa-
tionally exposed. This is in line with a previous study by
Kanerva et al. (13) who reported positive reactions in 48
out of 275 (17.5%) patientswith ahistory of occupational
exposure to (meth)acrylates.
Between January 1993 and January 2002, we tested
32 patients with the (meth)acrylate series, and only 3
(9.4%) of them developed a positive reaction. Between
2002 and 2011, a total of 104 patients were tested,
and 15 (14.4%) of them had positive reactions. The
(meth)acrylate series was patch tested in 16 patients
during the last year, and 6 (37.5%) of them have had
positive reactions so far. This increase may be explained
by themore frequentuseof (meth)acrylates (14).Another
plausible explanation is the selection of our patients who
are eligible for patch testing. In addition, the patch test
procedure has been improved over the years. Handling
of the acrylate allergens was improved by storing them
in a refrigerator and preparing them only minutes before
application, to prevent evaporation and thus optimize
the patch test concentration. Another improvement
was the reading of the results on D7, to pre-empt
late reactions. Eight of the 88 positive reactions were
exclusively identified onD7; however, all of these patients
had reacted to other acrylates on D3. However, for
an accurate and complete diagnosis, an additional D7
reading is recommended.
Most positive reactions in our (meth)acrylate series
were elicited by 2-HPA, 2-HEA, 2-HPMA, and DEGDA.
In a comprehensive overview, Kanerva et al. (13) found
a similar ranking, with 2-HEA (16/132), 2-HPMA
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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(29/242) and 2-HPA (14/132) in the top four. DEGDA
(13/243)was ranked 10th, but this acrylate causedmore
positive reactions (23/66) in the more recent overview
by Aalto-Korte et al. (3), who tested 541 patients and
found that 75 of them reacted to at least one acrylate.We
did not observe positive reactions to urethane diacrylate
(aliphatic) (alUDA),which is known tobea rare sensitizer.
Even so, positive reactions to alUDA have been reported,
especially in association with artificial nails (2, 15, 16),
warranting inclusionof thisallergen in the (meth)acrylate
series.
Screening for (meth)acrylates is of real interest. Inclu-
sion of a few acrylates in the baseline series as a screening
tool for acrylate contact allergy has been proposed. A
hypothetical series of four acrylates [2-HPA, ethyleneg-
lycol dimethacrylate (EGDMA), ethoxylated bisphenol A
glycol dimethacrylate and trimethylolpropane triacry-
late] would have identified 92% of our patients.
Goon et al. (17) composed twodifferent acrylatemixes,
onewith triethylene glycol diacrylate (TREGDA) 0.1%, 2-
hydroxyethylmethacrylate (2-HEMA)1.0%, andEGDMA
1.0%, and another with TREGDA 0.1% and 2-HEMA
2.0%, to screen for acrylate sensitization in the base-
line series. Screening with the individual components
of these mixes would have identified fewer than half of
our patients, respectively 11 (45.8%) and 10 (41.7%),
although we did not investigate 2-HEMA at 2.0%, but
only at 1.0%.
Goon et al. (1, 2) tested 1632 patients, and 48 had
positive results to one or more (meth)acrylates. They
composed a hypothetical screening series containing 2-
HEMA, EGDMA, TREGDA, 2-HPMA, bisphenol A glycidyl
methacrylate, and 1,4-butanediol diacrylate (BUDA) or
1.6-hexanediol diacrylate (HDDA), which would have
identified all of their past patients (dental, industrial,
and nail) with suspected (meth)acrylate contact allergy.
However, in our cohort, 17 (70.8%) of our 24 patients
would have been identified with this series, irrespective of
whether BUDA or HDDAwas used.
Aalto-Korte et al. (3) produced a hypothetical screen-
ing series with four allergens (EGDMA, DEGDA, 2-HPMA,
and pentaerythritol triacrylate) that identified 92.4%
(61/66) of their occupationally exposedpatients,whereas
it identified only 17 (70.8%) of our 24 patients.
Owing to this discrepancy and the fact that a sub-
stantial number of our patients would have been missed,
we prefer to use a supplementary series containing 29
(meth)acrylate allergens in addition to the baseline series
in patients.
Isobornyl acrylate contact allergy
An additional case of contact allergy caused by isobornyl
acrylate is reported in this study. In thisoccupational case,
the sensitizers were uncured UV ink and acrylate coating.
With avoidance of these products, the skin problems of
the industrial process operator resolved. To date, 1 year
later, he is working at another department in the same
factory without any complaints.
Sensitization to isobornyl acrylate is uncommon. Our
study did not show any new cases of isobornyl acrylate
sensitization besides the index patient. Together with the
study by Busschots et al. (4), this means that only 3 cases
of isobornyl acrylate sensitization have been identified to
date.
Unfortunately, our index patient was only patch tested
with the 0.1% concentration, and declined further patch
testing. Otherwise, he would have been tested with the
dilution series to ascertain the lowest concentration able
to elicit a positive reaction to isobornyl acrylate (18). A
concentration of 0.1% is the preferred patch test concen-
tration for acrylates, because of the irritant potency and
the risk of active sensitization (19, 20). However, acry-
lates are known for their volatility, and recent studies
have shown a poor correlation between the measured
(lower) and the stated (higher) concentrations of acrylate
patch test concentrations (21, 22). In addition, a woman
suspectedofhavingoccupationally relatedcontactallergy
provoked by an adhesive containing 61% isobornyl acry-
late did not react to an isobornyl acrylate patch test (6).
Moreover, various workers exposed to acrylates showed
no reaction to isobornyl acrylate 0.1% (3, 5, 23). This,
together with the lack of evidence of sensitization to 0.1%
in other studies, compelled us to include a higher con-
centration of 0.3%. However, the concentration of 0.3%
turned out to be too high, and caused irritant reactions in
3 patients. These reactions consisted of ‘shiny skin’ in 2
patients and irritant papules on the corners of the patch
test chambers in the remaining subject. Although the
index patient was only patch tested with 0.1% isobornyl
acrylate, he did develop a 2+ positive reaction, which is in
linewith the patients reported byBusschots et al. (4),who
developed2+and3+positivepatch test reactionsatacon-
centration of 0.1%, making it a legitimate concentration
for showing sensitization.
Acrylates, which are chemically more similar to
isobornyl acrylate, were expected to cross-react with
isobornylacrylate.Given the fact thatnoneof the included
subjects showed any reaction to isobornyl acrylate, no
valid conclusions can be drawn regarding the cross-
reactivity of isobornyl acrylatewithother (meth)acrylates
in vivo. Furthermore, cross-reactivity of (meth)acrylates
with isobornyl acrylate seems to be less plausible, because
© 2013 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
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cross-reaction was not observed in this study and has not
been reported in the literature.
Conclusion
We have described an additional rare case of allergic
contact dermatitis caused by isobornyl acrylate.
Cross-reactivity between isobornyl acrylate and other
acrylates could not be shown in a selected group of
previously sensitized patients. The ideal patch test con-
centration for isobornyl acrylate seems to be 0.1%.
This study and the current literature provide insuffi-
cient support for isobornyl acrylate to be routinely used
in the (meth)acrylate patch test series at our department.
Isobornyl acrylate contact allergy seems to be rare. How-
ever, this allergen should be considered as a potential
sensitizer in individual cases.
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